Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Role of Postoperative Radiotherapy for Patients with Pathological Stage III Non-Small-Cell Lung Cancer after Curative Resection

근치적 절제술 후 병기3의 비소세포성 폐암에서 수술 후 방사선 치료의 역할

  • Kim, Mi-Young (Department of Radiation Oncology, Seoul National University College of Medicine) ;
  • Wu, Hong-Gyun (Department of Radiation Oncology, Seoul National University College of Medicine) ;
  • Kim, Hak-Jae (Department of Radiation Oncology, Seoul National University College of Medicine) ;
  • Heo, Dae-Seog (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Kim, Young-Whan (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Kim, Dong-Wan (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Lee, Se-Hoon (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Kim, Joo-Hyun (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Kim, Young-Tae (Department of Thoracic Surgery, Seoul National University College of Medicine) ;
  • Kang, Chang-Hyun (Department of Thoracic Surgery, Seoul National University College of Medicine)
  • 김미영 (서울대학교 의과대학 방사선종양학교실) ;
  • 우홍균 (서울대학교 의과대학 방사선종양학교실) ;
  • 김학재 (서울대학교 의과대학 방사선종양학교실) ;
  • 허대석 (서울대학교 의과대학 내과학교실) ;
  • 김영환 (서울대학교 의과대학 내과학교실) ;
  • 김동완 (서울대학교 의과대학 내과학교실) ;
  • 이세훈 (서울대학교 의과대학 내과학교실) ;
  • 김주현 (서울대학교 의과대학 흉부외과학교실) ;
  • 김영태 (서울대학교 의과대학 흉부외과학교실) ;
  • 강창현 (서울대학교 의과대학 흉부외과학교실)
  • Received : 2010.12.16
  • Accepted : 2011.03.15
  • Published : 2011.03.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To evaluate the outcomes and prognostic factors of postoperative radiotherapy (PORT) for patients with pathological stage III non-small-cell lung cancer (NSCLC) at a single institution. Materials and Methods: From 2000 to 2007, 88 patients diagnosed as having pathologic stage III NSCLC after curative resection were treated with PORT. There were 80 patients with pathologic stage IIIA and eight patients with pathologic stage IIIB in the AJCC 6th staging system. The majority of patients (n=83) had pathologic N2 disease, and 56 patients had single station mediastinal LN metastasis. PORT was administered using conventional technique (n=76) or three-dimensional conformal technique (n=12). The median radiation dose was 54 Gy (range, 30.6 to 63 Gy). Thirty-six patients received chemotherapy. Radiation pneumonitis was graded by the Radiation Therapy Oncology Group system, and other treatment-related toxicities were assessed by CTCAE v 3.0. Results: Median survival was 54 months (range, 26 to 77 months). The 5-year overall survival (OS) and disease free survival (DFS) rates were 45% and 38%, respectively. The number of metastatic lymph nodes was associated with overall survival (hazard ratio, 1.037; p-value=0.040). The 5-year locoregional recurrence free survival (LRFS) and distant metastasis free survival (DMFS) rates were 88% and 48%, respectively. Multiple stations of mediastinal lymph node metastasis was associated with decreased DFS and DMFS rates (p-value=0.0014 and 0.0044, respectively). Fifty-one relapses occurred at the following sites: 10 loco-regional, 41 distant metastasis. Grade 2 radiation pneumonitis was seen in three patients, and symptoms were well tolerated with anti-tussive medication. Grade 2 radiation esophagitis was seen in 11 patients. There were no grade 3 or more severe complications associated with PORT. Conclusion: Our retrospective data show that PORT for pathological stage III NSCLC is a safe and feasible treatment and could improve loco-regional control. The number of metastatic lymph nodes and stations of mediastinal lymph node metastasis were analyzed as prognostic factors. Furthermore, efforts are needed to reduce distant metastasis, which is a major failure pattern of advanced stage NSCLC.

목적: 본 연구는 근치적 절제술 후 병기 3의 비소세포성 폐암에서 방사선 치료의 결과와 이에 영향을 주는 예후 인자를 분석해 보고자 하였다. 대상 및 방법: 2000년부터 2007년까지 88명의 환자가 비소세포성 폐암으로 근치적 절제술 후 병기 3기로 진단받았고, 수술 후 방사선 치료를 시행 받았다 이중 80명의 환자가 병기 3A였으며, 8명의 환자가 병기 3B였다. 83명의 환자는 림프절 병기 N2였으며 이들 중 56명은 단일 부위(single-station)의 종격동 림프절 전이였다. 76명은 2차원, 12명은 3차원 입체조형치료로 수술 후 망사선 치료를 받았다. 총 선량은 30.6에서 63 Gy 였으며 중앙값은 54 Gy였다. 36명의 환자가 항암치료를 시행받았다. 결 과: 생존기간은 26~77개월이었다(중앙값, 54개월). 5년 생존율 및 무병생존율은 각각 45%, 38%였다. 전이된 림프절개수가 생존율에 영향을 미치는 인자로 분석되었다(hazard ratio, 1.037; p=0.040). 5년 국소제어율 및 원격 전이제어율은 각각 88%, 48%였다. 종격동 림프절 부위의 전이가 단일 부위(single-station)인 경우가 무병생존율(p=0.0014)과 원격전이제어율(p=0.0044)을 의미 있게 증가시켰다. 총 51명의 재발이 발생하였으며 국소구역 재발은 10명, 원격전이는 41명이었다. 10명의 국소구역 재발 중에 6명은 방사선 치료 범위 내에서 재발하였다. Radiation Therapy Oncology Group(RTOG) 2도의 방사선 폐렴은 3명의 환자에서 보였으며 증상은 진해성 약제만으로도 조절이 잘 되었다. CTCAE 2도의 방사선 식도염은 11명의 환자에서 관찰되었다. 수술 후 방사선 치료로 인한 3도 이상의 심각한 부작용은 관찰되지 않았다. 결 론: 본 연구에서 국소 진행 비소세포성 폐암에서 근치적 수술 후 방사선 치료는 안전하고 임상적으로 적용 가능한 치료법이며, 국소제어를 증가시킬 수 있는 것으로 분석되었다. 예후인자로는 전이된 림프절 개수와 종격동 림프절 부위가 생존율에 영향을 미치는 것으로 분석되었다. 또한 국소 진행 비소세포성 폐암의 대부분의 재발 형태인 원격 전이를 감소시키기 위한 추가적인 노력이 필요할 것으로 생각된다.

Keywords

References

  1. Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer 1999;86:1867-1876 https://doi.org/10.1002/(SICI)1097-0142(19991101)86:9<1867::AID-CNCR31>3.0.CO;2-9
  2. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 1998;352:257-263 https://doi.org/10.1016/S0140-6736(98)06341-7
  3. Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol 2006;24:2998-3006 https://doi.org/10.1200/JCO.2005.04.6110
  4. Keller SM, Adak S, Wagner H, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 2000;343:1217-1222 https://doi.org/10.1056/NEJM200010263431703
  5. Bradley JD, Paulus R, Graham MV, et al. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705. J Clin Oncol 2005;23:3480-3487 https://doi.org/10.1200/JCO.2005.12.120
  6. Feng QF, Wang M, Wang LJ, et al. A study of postoperative radiotherapy in patients with non-small-cell lung cancer: a randomized trial. Int J Radiat Oncol Biol Phys 2000;47:925-929 https://doi.org/10.1016/S0360-3016(00)00509-5
  7. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-2597 https://doi.org/10.1056/NEJMoa043623
  8. Arriagada R, Bergman B, Dunant A, et al. Cisplatinbased adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-360 https://doi.org/10.1056/NEJMoa031644
  9. Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual. 6th ed. New York: Springer-Verlag, 2002
  10. Edge SB, Byrd DR, Compton CC, et al. AJCC cancer staging manual. 7th ed. New York: Springer-Verlag, 2009
  11. Byhardt RW, Martin L, Pajak TF, Shin KH, Emami B, Cox JD. The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non-small cell lung cancer (NSCLC): analysis of a Radiation Therapy Oncology Group (RTOG) protocol. Int J Radiat Oncol Biol Phys 1993;27:537-544 https://doi.org/10.1016/0360-3016(93)90377-8
  12. Socinski MA, Rosenman JG, Halle J, et al. Doseescalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial. Cancer 2001;92:1213-1223 https://doi.org/10.1002/1097-0142(20010901)92:5<1213::AID-CNCR1440>3.0.CO;2-0
  13. Rosenman JG, Halle JS, Socinski MA, et al. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys 2002;54:348-356 https://doi.org/10.1016/S0360-3016(02)02958-9
  14. Kong FM, Ten Haken RK, Schipper MJ, et al. Highdose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 2005;63:324-333 https://doi.org/10.1016/j.ijrobp.2005.02.010
  15. Spoelstra FO, Senan S, Le Pechoux C, et al. Variations in target volume definition for postoperative radiotherapy in stage III non-small-cell lung cancer: analysis of an international contouring study. Int J Radiat Oncol Biol Phys 2010;76:1106-1113 https://doi.org/10.1016/j.ijrobp.2009.02.072
  16. Keller SM, Vangel MG, Wagner H, et al. Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease. J Thorac Cardiovasc Surg 2004;128:130-137 https://doi.org/10.1016/j.jtcvs.2003.11.061
  17. Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 2000;18:2981-2989
  18. Sawabata N, Keller SM, Matsumura A, et al. The impact of residual multi-level N2 disease after induction therapy for non-small cell lung cancer. Lung Cancer 2003;42:69-77 https://doi.org/10.1016/S0169-5002(03)00245-9
  19. Matsuguma H, Nakahara R, Ishikawa Y, et al. Post-operative radiotherapy for patients with completely resected pathological stage IIIA-N2 non-small cell lung cancer: focusing on an effect of the number of mediastinal lymph node stations involved. Interact Cardiovasc Thorac Surg 2008;7:573-577 https://doi.org/10.1510/icvts.2007.174342
  20. Sawyer TE, Bonner JA, Gould PM, et al. Effectiveness of postoperative irradiation in stage IIIA non-small cell lung cancer according to regression tree analyses of recurrence risks. Ann Thorac Surg 1997;64:1402-1407 https://doi.org/10.1016/S0003-4975(97)00908-9